recommendation in Europe just a google translate but better than nothing
Imagin Medical: potential for share price multiplication thanks to a miracle weapon against bladder cancer
04.06.2018 - Dear Readers,
| |
| |
 | WKN | A2AE35 | ISIN | CA45250L1058 | SYMBOL | DPD2 | COURSE | CAD 0.26 | PRICE TARGET | CAD 1.30 | OTHERS | | Urologists buy
Imagin Medical shares | |
almost every one of us knows someone who has or has had cancer. For many it is equivalent to a death sentence, but the earlier a tumor is detected, the better it can be treated and the greater the chances of recovery.
Bladder cancer is probably one of the most home-treacherous cancers, as tumor tissue can grow for years without the patient having significant discomfort. However, early detection of urinary bladder cancer shows a chance of recovery of more than 90 percent. However, patients with bladder cancer discovered at a late stage have a high mortality risk. Urologists around the world have been waiting for decades for better tools to detect and treat bladder cancer at an early stage.
We have found an innovative company with a stock market value of just 21.7 million euros, which could provide urologists with a long-awaited miracle weapon in the fight against bladder cancer and could significantly improve the chances of recovery of patients. Due to the extremely low valuation, the high quality of the technology and the short approval procedure in the USA (around 12 months), we see a potential for multiplication for the share of Imagin Medical Inc. (WKN: A2AE35) .
Billions of bladder cancer market
The National Cancer Institute estimated that in 2016, approximately 1.685 million new cancer cases will be diagnosed in the US and 595,690 people will die of the disease. These are dramatic numbers. The treatment of bladder cancer is the most expensive.
All in all, the cost of this cancer in the US alone is $ 4 billion a year! In non-muscle invasive bladder cancer (75 percent of all cases) the relapse rate is over 50 percent. More than 600,000 people live in daily fear that the cancer will recur.
Source: seer.cancer.gov/statfacts/html/urinb.html
We see further potential in using the i / Blue ™ solution in other areas where endoscopes are used for minimally invasive examinations or interventions (eg laparoscopy).
The global endoscopy equipment market was $ 29.59 billion in 2015 and is projected to reach $ 41.81 billion by 2021, according to Zion Research experts ( Source: www.globenewswire.com/news-release/2018/05 / 17 /
1508299/0 / en / Global-Endoscopy-Devices-Market-Share-Projected-to-reach-USD-41-813-42-million-by-2021-Zion-Market-Research.html ).
The i / Blue ™ imaging system - better and faster than the gold standard
Bladder cancer is usually detected by an endoscope using visible white light (over 90 percent market share), and it is not easy to distinguish the cancerous cells from normal tissue. To date, physicians have tremendous difficulty in clearly recognizing the edges of a tumor using its existing capabilities, resulting in not all cancer cells being removed during surgery. This also explains why the relapse rate of bladder cancer is so immense.
In the meantime, blue light endoscopes using fluorescence are also being used, which makes it easier to detect and remove tumors. A major disadvantage, however, is the waiting time of one hour before the contrast agent was taken up by the bladder. This poses enormous challenges for hospitals, making this method of investigation ultimately impractical and expensive.
Another disadvantage is that the treating physician must switch between two different monitors in this technology to accurately assess the details of the tumor and its exact location. On one monitor he sees the complete bladder and on the other a highlighted image of the cancer, but without specifying its exact location in the bladder.
Imagin Medical's patented i / Blue ™ Imaging solution is 100 times more sensitive than traditional systems, requires 90 percent less contrast, and delivers more accurate demarcation of the tumor on a single monitor - in less than 15 minutes!
Around 90 percent of all endoscopes currently on the market could easily be upgraded with the Imagin Medical system and, in the end, significantly reduce not only examination costs but also the relapse rate for bladder cancer.
The management team knows how to convince
Having a good product is only part of a successful business. If you can not get an idea right, even a great product does not help much. Jim Hutchens, the CEO of Imagin Medical, is a successful entrepreneur with over 30 years of experience in the medical device industry.
He was the founder and CEO of Microsurge Inc. and Choice Therapeutics. The latter was sold to the listed Alliqua Biomedical. Mr. Hutchens also held senior positions at Microvasive Endoscopy, a division of Boston Scientific, as well as at Smith & Nephew and Millipore. He is a former member of the Board of Directors of Brigham and Women's Faulkner Hospital.
Jim Hutchens knows exactly how to develop the distribution channels to bring a medical device product to market successfully. He shows this in the following interview:
Source: www.youtube.com/watch?v=We3MHQnh8nw&t=1147
Jim Hutchens has gathered a number of top executives to create the best conditions for Imagin Medical's success.
Thom Mahon, Sales Director of Imagin Medical, has been selling and marketing medical devices for over 35 years. He was the owner and president of Urolaze, an independent urology specialist, and has over 25 years served in various sales and marketing positions at KARL STORZ SE & Co. KG of Germany ( www.karlstorz.com ), the leading provider of endoscopes , inside.
Pam Papineau, Director of Regulatory Affairs at Imagin Medical, has more than 30 years of quality and regulatory experience with Baxter, Boston Scientific and Cogentix (Vision Sciences), and has acted as a consultant on a variety of devices including Endoscopy, imaging, orthopedics and cardiovascular.
She has successfully prepared dozens of FDA regulatory filings and EU technical files to support the CE Marking of a wide range of medical devices and has monitored numerous clinical trials. Pam Papineau will work with Hogan Lovells, Imagin Medical's law firm, to prepare for meetings with the FDA and follow-up to the regulatory process.
John Vacha, Imagin Medical's CFO, has 20 years of experience in the healthcare industry and worked for Intact Medical Corp. for seven years before being acquired by Medtronic last year. Previously, he was a Senior Advisor at Deloitte & Touche, LLP.
The advisory board of Imagin Medical includes Dr. med. Edward Messing, Chief of Urology Unit at the University of Rochester Medical Center ( www.urmc.rochester.edu ) and Stavros Demos, Ph.D., the inventor of the i / Blue ™ imaging solution and Senior Scientist and Group Leader of the Optical Materials Group at the University of Rochester Laboratory for Laser Energetics (LLE) in New York.
Urologists privately buy Imagin Medical shares
If you are still not convinced, you should read the following statement carefully:
Dr. Stanley J. Swierzewski, Chief Surgeon & Director of Urology at Holyoke Medical Center, Massachusetts: "As a practicing urologist, I have invested in Imagin Medical because I have a duty and responsibility to drive improvements in the treatment and technology that benefits and benefits my patients The current technology is cumbersome and time-consuming, making it less effective as a screening or control device Bladder cancer patients are generally monitored for life with cystoscopies in practice that are not effective in distinguishing between inflammation and cancer I am confident I'm looking forward to the results of the research study and I can not wait to use this technology to treat my bladder cancer patients. "
Besides Dr. Swierzewski has also Roger Buckley, Head of Urology Division at North York General Hospital, Toronto, privately involved in Imagin Medical.
CONCLUSION: The stock market value of Imagin Medical Inc. (WKN: A2AE35) currently stands at just C $ 32.82 million, offering plenty of room for significant price appreciation. The last capital increase was clearly oversubscribed and spilled nearly 4 million CAD into the fund.
Imagin Medical has completed the development of the Alpha B prototype and is testing it at the University of Rochester with five volunteers. Based on these results, the prototype will be revised and its production costs will be further reduced. The new prototype is expected to lead to preliminary talks with the FDA in the summer of 2018. The FDA approval process in medical technology should take an estimated 12 months. If everything goes according to plan, the product launch could already take place in the middle of 2019.
Source: imaginmedical.com
There is no doubt that urologists have an acute need for a convenient and highly accurate imaging system for better diagnosis and treatment of bladder cancer. The i / Blue ™ solution from Imagin Medical has the best prerequisites to become the new gold standard in bladder examinations. Especially doctors' practices would get a powerful system for the first time.
The management of Imagin Medical estimates that only 7-10 sales people will be needed to market the high-margin product. But we expect Imagin Medical to be acquired after FDA approval. It's no secret that many medical technology companies are growing through acquisitions. Imagin Medical would be a perfect takeover candidate.
We regard the opportunity / risk ratio as excellent and see the share price of Imagin Medical Inc. (WKN: A2AE35) as 12 months ahead as target price of 1.30 CAD or 0.86 EUR. In the medium term, we can imagine a good ten times the current level if Imagin Medical is not previously acquired by a major competitor, such as Karl Storz or Olympus ( www.olympus-global.com ).
We expect a series of corporate news in the coming weeks and months that should act as price catalysts. On Twitter, Imagin Medical announced "big news" for the current month at the weekend.
The stock can be traded cheaply on Tradegate, in Stuttgart and Frankfurt or directly in Canada. Please always limit your purchase orders.
Best regards,
Your PROFITEER editorial staff
Image sources: imaginmedical.com ,
seer.cancer.gov/statfacts/html/urinb.html ,
www.youtube.com/watch?v=We3MHQnh8nw